Launching the first blood-based early breast cancer detection test

Proteomics reveals what's happening now.
With clarity.
Proteins are the body's molecular messengers, carrying information about health and disease. Cancer changes the protein landscape in ways that can be detected long before symptoms appear. Our proprietary technology analyzes thousands of proteins simultaneously, creating a comprehensive molecular fingerprint that reveals the earliest signs of cancer with unprecedented accuracy.
Introducing Certitude®
A simple, accurate blood test to help detect breast cancer, especially in women with dense breasts or elevated risk. It doesn't replace imaging; it works alongside it as a powerful partner in your screening plan.
Certitude® uses Astrin's patented deep proteomic platform to distinguish healthy individuals from those with early-stage breast cancer, all from a small blood sample.

We've unlocked early with deep proteomics and AI.
Our breakthrough platform detects cancer at its earliest stage by analyzing what's happening in the body, in real time.
Astrin Biosciences is a cancer intelligence company built to push the boundaries of technology — accelerating early cancer detection and advancing cancer care.
Certitude detects ~9 out of 10 early stage breast cancers even in patients with high density.
Proteins analyzed simultaneously in a single test for comprehensive cancer screening.
Years of research and development in proteomics and AI for early cancer detection.